Analysis: Japan’s Drug Makers See Price Cuts Under U.S. Democrat
This article was originally published in PharmAsia News
Executive Summary
Japan's drug makers can expect to be affected by the presidential election in the United States in November, according to analysts. One element that cannot be avoided regardless of the party in the White House is the fact generics will spread through the U.S. market as patents on Japanese drugs and others expire. Overall, however, because Democrats tend to favor government guarantees for health care, there will be a pressure to keep drug prices down. Analysts cite statistics of slow pharmaceutical price growth under previous Democratic administrations, faster growth under Republicans. (Click here for more - a subscription may be required